866-997-4948(US-Canada Toll Free)

Follicular Thyroid Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Jul 2015

Category :

Cancer

No. of Pages : 91 Pages

Follicular Thyroid Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Follicular Thyroid Cancer - Pipeline Review, H2 2015, provides an overview of the Follicular Thyroid Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Follicular Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Follicular Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Follicular Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Follicular Thyroid Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Follicular Thyroid Cancer - Overview 7
Pipeline Products for Follicular Thyroid Cancer - Comparative Analysis 8
Follicular Thyroid Cancer - Therapeutics under Development by Companies 9
Follicular Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 10
Follicular Thyroid Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Follicular Thyroid Cancer - Products under Development by Companies 14
Follicular Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Follicular Thyroid Cancer - Companies Involved in Therapeutics Development 16
AstraZeneca Plc 16
Eisai Co., Ltd. 17
Exelixis, Inc. 18
Novartis AG 19
Pfizer Inc. 20
Follicular Thyroid Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
cabozantinib s-malate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dabrafenib mesylate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
everolimus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
lenvatinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pasireotide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
sunitinib malate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tetraiodothyroacetic acid - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
vandetanib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Follicular Thyroid Cancer - Recent Pipeline Updates 60
Follicular Thyroid Cancer - Dormant Projects 87
Follicular Thyroid Cancer - Product Development Milestones 88
Featured News & Press Releases 88
May 06, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains European Orphan Drug Status 88
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 88
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables
Number of Products under Development for Follicular Thyroid Cancer, H2 2015 7
Number of Products under Development for Follicular Thyroid Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Follicular Thyroid Cancer - Pipeline by AstraZeneca Plc, H2 2015 16
Follicular Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2015 17
Follicular Thyroid Cancer - Pipeline by Exelixis, Inc., H2 2015 18
Follicular Thyroid Cancer - Pipeline by Novartis AG, H2 2015 19
Follicular Thyroid Cancer - Pipeline by Pfizer Inc., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Follicular Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2015 60
Follicular Thyroid Cancer - Dormant Projects, H2 2015 87

List of Figures
Number of Products under Development for Follicular Thyroid Cancer, H2 2015 7
Number of Products under Development for Follicular Thyroid Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Top 10 Targets, H2 2015 22
Number of Products by Stage and Top 10 Targets, H2 2015 22
Number of Products by Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Top 10 Routes of Administration, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
Number of Products by Top 10 Molecule Types, H2 2015 28
Number of Products by Stage and Top 10 Molecule Types, H2 2015 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *